Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

September 11, 2019

Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’

News

Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to ... Read more

August 28, 2019

GSK’s Belantamab Mafodotin Shows Promise for Relapsed or Refractory Multiple Myeloma

News

GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase 2 trial, with the trial meeting its ... Read more

August 26, 2019

Darzalex OK’d to Treat Multiple Myeloma Patients in Japan Not Eligible for Stem Cell Transplant

News

People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination of Darzalex (daratumumab) and standard treatment, the companies behind the therapy announced. ... Read more

August 7, 2019September 10, 2019

clonoSEQ Assay Approved in New York to Measure MRD in Myeloma, Other Blood Cancers

News

The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample — now is available to New ... Read more

August 5, 2019

First Patient Dosed in Phase 1 Trial of Antibody for Advanced Multiple Myeloma, Teneobio Announces

News

A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial is recruiting people with advanced ... Read more

July 31, 2019

Donor-derived CAR T-cell Therapy ALLO-715 Enters Clinical Testing for Multiple Myeloma

News

Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed prior therapies. This follows the recent approval ... Read more

July 15, 2019

Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests

News

A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new study suggests. Testing for ... Read more

July 12, 2019July 15, 2019

FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma

News

The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential therapy for patients with hard-to-treat multiple myeloma, ... Read more

May 29, 2019May 29, 2019

Open Enrollment for Phase 1 Trial Testing CS1-CAR T-Cell Therapy for Hard-to-Treat Myeloma

News

A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang Bio’s investigational autologous (patient-derived) CS1-chimeric antigen receptor (CAR) T-cell therapy. The ... Read more

May 20, 2019

Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA

News

Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have failed at least ... Read more

Pin It on Pinterest